The ANDA product that independently developed by Yaopharma Co., Ltd. named Entecavir Tablets (0.5mg, 1mg), was approved by the US FDA on Nov. 04, 2019. It marks Yaopharma’s continuous improvement in exploring the international pharmaceutical markets, and its R&D system and quality system are recognized internationally once again.

Entecavir Tablets is indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT) or histologically active disease. Entecavir is currently the first-line antiviral drug for patients with chronic hepatitis B .

It has been reported that Yaopharma’s Entecavir Tablets has passed the consistency evaluation on generic drugs and been approved in China, and ranks on the top three of the domestic similar product which passed the consistency evaluation.